Viewing data from:

TINIDAZOLE

ANDA

TINIDAZOLE | A201172 | HIKMA PHARMACEUTICALS USA INC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Tinidazole (2023)

Total Spending

$385K

Total Claims

8,310

Beneficiaries

6,633

Avg Cost/Unit

$3.57

Spending Trend

$24K(2019)→$66K(2020)→$238K(2021)→$356K(2022)→$385K(2023)

YoY Change:-10.6%

5yr CAGR:+2.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF5 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

ZHEJIANG SUPOR PHARMACEUTICALS CO LTDTINIDAZOLE (NON-STERILE DRUG SUBSTANCE)

DMF 188242005

PFIZER INCInactiveTINIDAZOLE BULK

DMF 17041971

PFIZER LABORATORIES DIV PFIZER INCInactiveTINIDAZOLE

DMF 62261985

FARCHEMIA SRLInactiveTINIDAZOLE USP XXI

DMF 62751986

PFIZER SAInactiveTINIDAZOLE

DMF 65441986

ZAKLADY FARMACEUTYCZNE POLPHARMA SAInactiveTINIDAZOLE

DMF 103501993

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 250MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Apr 30, 2012

No patent or exclusivity listings for this strength.

#002 — 500MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Apr 30, 2012